Proffered Paper: Inhibition of RNA Polymerase I transcription by CX-5461 as a completely new approach to treat highly refractory haematological malignancies
Loading...
Date
Authors
Hannan, R.
Hein, Nadine
O’Brien, S. E.
Drygin, D.
Cullinane, C.
Matthews, G.
Johnstone, R.W.
Pearson, R.B.
McArthur, G.
Harrison, S.
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Recent findings by our group have been instrumental in the
development of the novel selective inhibitor of RNA Polymerase I (Pol I),
CX-5461 (Drygin et al., Cancer Research, 2011; Bywater et al. Cancer Cell,
2012). This work has led to the fundamental discovery that ribosomal gene
transcription by Pol I is not simply a ‘house keeping’ process in cancer cells but
is highly regulated to maintain their viability (Bywater et al., Nature Reviews
Cancer 2013). Strikingly, inhibition of Pol I transcription shows a profound
selectivity for malignant over normal cells in preclinical studies.
Description
Keywords
Citation
Collections
Source
European Journal of Cancer: 23rd Biennial Congress of the European Association for Cancer Research, 5–8 July 2014, Munich, Germany